China National Pharmaceutical Group (Sinopharm), a State-Owned Enterprise that is China’s largest drug maker, will be re-organized into a hybrid ownership structure that includes participation from private sources. The exact nature of the model has not been disclosed and, in fact, China officials may not have settled on a specific plan. The reform is part of a larger effort in China to privatize at least six SOEs following several different re-organization models.
Help employers find you! Check out all the jobs and post your resume.
